Findings
========

Human *Papillomavirus* (HPV) infection is a particularly difficult problem for human immunodeficiency virus (HIV)-infected women because they are more vulnerable to infection and less likely to clear the virus, which increases their risk of developing cervical lesions and cancer \[[@B1]\]. Specifically, there are differences in the prevalence, incidence, progression and regression of HPV-related cervical diseases in HIV-infected women compared to HIV-uninfected women. Moreover, in HIV-infected women, cervical cancer (CC) responds poorly to recommended therapies, behaves more aggressively, and in cases of recurrence, has a poorer prognosis \[[@B1],[@B2]\]. The severe impact of HIV in relation to CC was demonstrated in a study that showed that HIV-positive women had an almost five fold greater chance of developing precancerous lesions than did HIV-uninfected women \[[@B3]\].

In cervical carcinogenesis, the integration of high-risk HPV (HR-HPV) into host-cell chromosomes is followed by the binding of HPV E6 and E7 oncoproteins with tumor suppressor proteins *p53* and *pRb*, respectively. This process results in impaired tumor suppressor gene function, involving DNA repair, decreased apoptosis, deregulation of key controls in cell proliferation, and eventual cell immortalization \[[@B4]\].

The *p53* tumor suppressor gene specifically inhibits cell cycle progression and promotes DNA repair and/or apoptosis; its inactivation is correlated with a critical step in the development of many human cancers. Inactivation may result from a number of events, including mutation of the *p53* gene (with or without associated allelic deletions) and binding of the *p53* gene to cellular or viral proteins, such as the HPV E6 oncoprotein \[[@B5]\]. *p53* mutations are mostly missense in nature and are located predominantly within the DNA-binding domain, where a single mutation is sufficient to cause loss of normal *p53* function \[[@B6]\]. Studies on the association between CC and the loss of *p53* function have yielded conflicting results \[[@B5],[@B7],[@B8]\].

Mutations in the *p53* gene occur most frequently within exons 5--8, which is the highly conserved DNA binding domain region \[[@B9]\]. Studies on *p53* that included all exons have suggested that mutations outside exons 5--8 are rare in tumors \[[@B10]\]. However, most studies on the involvement of the *p53* gene in cervical carcinogenesis are related to its protein expression by immunohisto/cytochemical or polymorphism in condon-72 \[[@B5],[@B7]\]. To our knowledge, no previous studies have analyzed the mutations in exons 5--8 of the *p53* gene in HIV- and HPV-infected women. In our study, we verified these mutations in women with and without cervical abnormalities.

The study included cervical samples of 160 women who were divided into three groups: (1) 83 HPV- and HIV-infected (HIV group); (2) 37 HPV-infected/HIV-uninfected (control group); and (3) 40 cervical samples from women with normal cytology/DNA-HPV negative/HIV-uninfected that were only used as a negative control for the mutation of the *p53* gene exons (negative control *p*53 reactions). The women included in the study were enrolled in the Specialized Assistance Service (SAE) for sexually transmitted diseases (STD)/AIDS in Maringá, Brazil, between April 1, 2011, and October 30, 2011. In these samples, HPV-DNA was previously detected (data not shown) in the Clinical Cytology Laboratory at the State University of Maringá (UEM), Brazil, and stored at -80°C. Stored samples from HIV-infected and HIV-uninfected women, both with and without cervical lesions, were included in the study. The samples for 1 and 2 groups were also HPV-DNA positive.

Cervical and endocervical samples were collected using a cytobrush and an Ayre's spatula, transferred to 1.5 ml tubes with 1.0 ml of sterile 0.9% NaCl solution, and stored at -80°C. Genomic DNA was extracted using the AxyPrep™ Body Fluid Viral DNA/RNA Miniprep Kit (AP-MN-Bf-VNA-50, Axygen, CA, USA) according to the manufacturer's instructions. The quality and quantity of purified DNA were measured by spectrophotometry. HPV polymerase chain reaction (PCR) amplification for HPV was conducted using primers MY09 (5′CGTCCMAARGGAWACTGATC-3′) and MY11 (5′-GCMCAGGGWCATAAYAATGG-3′); co-amplification of the human β-globin gene was performed as an internal control using primers GH20 (5′-GAAGAGCCAAGGACAGGTAC-3′) and PC04 (5′-CAACTTCATCCACGTTCACC-3′) under the same conditions as for the HPV-PCR \[[@B11]\]. The cytological smears were prepared with a portion of the collected material and were reported according to the Bethesda System \[[@B12]\]: normal, without altered cells; atypical squamous cells of undetermined significance, cannot exclude high-grade squamous intraepithelial lesion (ASC-H); low-grade squamous intraepithelial lesion (LSIL); or high-grade squamous intraepithelial lesion (HSIL). Cases with a cytological diagnosis of HSIL were confirmed by histopathology.

For HPV genotyping of selected samples, a new HPV-PCR amplification was performed, which was followed by PCR-Restriction Fragment Length Polymorphism (PCR-RFLP) analysis using *Hpy*CH4V \[[@B13]\]. The mutations of the *p53 g*ene was verified by PCR-Single Strand Conformational Polymorphism (PCR-SSCP), which detects molecular changes in single-stranded DNA that cause changes in electrophoretic mobility \[[@B8]\]. The following primers were used: exon 5 (5′-TGTTCACTTGTGCCCTGACT-3′) / (5′-AGC AAT CAG TGA GGA ATC AG-3′), 310 bp; exon 6 (5′-TGGTTGCCCAGGGTCCCCAG-3′) / (5′-TGGAGGGCCACTGACAACCA\--3′), 223 bp; exon 7 (5′-CTTGCCACAGGTCTCCCCAA-3′) / (5′-AGGGGTCAGCGGCAAGCAGA-3′), 248 bp; and exon 8 (5′-TTGGGAGTAGATGGAGCCT-3′) / (5′-AGAGGCAAGGAAAGGTGATA-3′), 213 bp. This is a simple technique which allows the identification of samples with type missense mutation, as well as correlation with the expression of mutated *p53*\[[@B14]\]. The women signed a consent form, and this study was approved by the Committee for Ethics in Research Involving Humans at the State University of Maringá (UEM)/Paraná, Brazil (No. 085/2011).

The statistical analysis was performed using STATISTICA 8.0 software, and all of the variables were expressed as absolute and relative frequencies. The rates of *p*53 exon mutations in the groups of women were compared using a non-parametric Z test. A p value \< 0.05 was considered statistically significant.

On average, the HIV group was older than the control group (40.9 ± 11.23 *vs* 35.7 ± 10.57 years old; p *=* 0.0254). The majority of the HIV group showed excellent control of the HIV infection, as determined by the correct use of highly active antiretroviral therapy (HAART) (79.2%), current CD4+ T lymphocyte count \> 350 cells/mm^3^ (73.6%) and current viral load \< minimum limit (58.4%) or between the minimum limit and 100 copies/mL (38.8%).

The most common HR-HPV in the HIV group were HPV-51 and HPV-16 (n = 11/83, 13.5% each). Of these samples, a *p53* mutation occurred in only 1 sample of HPV-16 (9.1%) and in 6 samples of HPV-51 (54.5%). For the control group, HPV-16 (n = 6/37, 16.2%) and HPV-66 (n = 5/37, 13.5%) were the most common, but the *p53* mutation was observed in only 1 sample each (16.7% and 20.0%, respectively). HPV-58 was detected in 2 samples, and the mutation occurred in these 2 samples (100%). In regards to the cytological findings, the HIV group showed the following: 70 normal, 2 ASC-H, 10 LSIL and 1 HSIL. The findings in the control group were as follows: 21 normal, 6 ASC-H, 9 LSIL and 1 HSIL (Table  [1](#T1){ref-type="table"}).

###### 

**Distribution of mutations in the*p53*gene in HIV group and control group**

  **Cytologic findings**    **Total samples**   ***p53*mutation**   **Total samples**   ***p53*mutation**   ***\**p**                      
  ------------------------ ------------------- ------------------- ------------------- ------------------- ----------- ------- ---- ------ --------
  Normal Cytology                  70                 84.3                 12                 17.1             21       56.8    4    19.0   0.4956
  ASC-H                             2                  2.4                  1                 50.0              6       16.2    \-    \-   
  LSIL                             10                 12.1                  2                 20.0              9       24.3    3    33.3   0.3303
  HSIL                              1                  12                   1                 100.0             1        2.7    \-    \-   
  TOTAL                            83                 100.0                16                 19.3             37       100.0   7    18.9   0.4896

*HPV*, human papillomavirus; *HIV*, human immunodeficiency virus; cytologic findings (according to Bethesda System 2001): atypical squamous cells of undetermined significance, cannot exclude high-grade squamous intraepithelial lesion (ASC-H); low-grade squamous intraepithelial lesion (LSIL); high-grade squamous intraepithelial lesion (HSIL).

\*p \< 0.05 was considered significant.

Figure  [1](#F1){ref-type="fig"}(a) shows a mutation in exon 6 as an example of abnormal bands of the *p53* gene. In total, 19.3% of the HIV group and 18.9% of the control group (p = 0.4896) showed mutations in the *p53* gene and all had HR-HPV. As previously described, no mutations occurred in any of the negative control *p*53 reactions \[[@B15]\] which is baseline condition this population. A mutation in exon 7 alone or together with a mutation in exon 6 was the highest in the HIV group (43.8%), and a mutation in exon 6 was highest in the control group (57.2%) (p = 0.0793) (Figure  [1](#F1){ref-type="fig"}b). However, because the p value was close to being statistically significant, these data may suggest a tendency toward mutations in exon 7 in the HIV group.

![**Mutation in exon 6 of the*p53*gene in the HIV group compared with the control group.** Panel **a**: Electrophoretic analysis of cervical *p53* gene mutations using PCR-Single Strand Conformational Polymorphism (PCR-SSCP) in an 8% polyacrylamide gel stained with ethidium bromide. Samples A1-A3, negative for *p53* gene mutations; A4, positive for *p53* gene mutation (arrow); C, negative control *p*53 reactions; M, 25 bp molecular weight marker. Panel **b**: The frequency of mutations in *p53* exons 5 to 8 in both groups. Exon 7 and exon 6 were the most mutated exons examined in the HIV group and in the control group, respectively.](1750-9378-8-38-1){#F1}

In the HIV group, a mutation in exon 7 occurred at the highest frequency in normal cytology (31.3%) followed by LSIL and HSIL (6.3% for both). For the control group, a mutation in exon 6 was most common in both normal cytology and LSIL (28.6% each) (Table  [1](#T1){ref-type="table"}). There was no difference in mutation rates in normal cytology or lesions in both groups (p = 0.4956 and 0.3303, respectively; Table  [1](#T1){ref-type="table"}).

These findings suggested that the HPV infection appears to lead to a mutation in the *p53* gene in different exons in HIV-infected and HIV-uninfected women, i.e., mainly in exons 7 and 6, respectively. A point mutation at the splice donor site at the 3′ end of exon 7 of the human *p53* gene results in the retention of the intron 7 sequence in the mRNA, thereby inactivating the *p53* protein \[[@B16]\].

We also showed that the total mutation in *p53* gene exons 5--8 was not significantly associated with the HIV and control groups, and in women of both groups with normal cytology or different grades of cervical abnormalities, similar to those described for *p53* gene condon 72 polymorphism \[[@B7]\] and *p53* gene immunoexpression \[[@B5]\] in HIV-uninfected women. Interestingly, the samples from the HIV group with HPV-51 showed the highest rates of mutations in the *p53* gene which deserves further studies. Overall, higher rates of cervical HPV infection and CC can be partly related to a more specific mutated exon in HIV-infected patients.

Through its effect on CD4 cells and regulation of immune responses to a variety of antigens, HIV infection may attenuate the systemic immune response to HPV. It is speculated that if there is a low number of circulating HPV-specific memory cells, then HPV-specific immunity may be particularly vulnerable to the effects of HIV. Possible due to this HIV-infected women are more vulnerable to infection and less likely to clear the virus, which increases their risk of developing cervical lesions and cancer \[[@B1]\]. According to this hypothesis, HPV-specific immunity may not recover fully after immune response is restored, which may explain the relatively limited beneficial effect of HAART on HPV cervical infection and CC \[[@B17]\].

Conclusions
===========

In conclusion, we acknowledge that we did not study women with CC, and we studied few women with HSIL. However, our study cannot exclude the possibility that the mutations in the *p53* gene may act at later stages of carcinogenesis. Nevertheless, we believe that our study provides preliminary evidence that the mutation in exon 7 might be an important differentiating factor for cervical carcinogenesis in HIV-infected women. This aspect deserves an additional cross-sectional and longitudinal study using a larger sample size with a higher number of HSIL to observe the evolution of cervical lesions.
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